Navire Pharma is developing small molecules to treat cancers driven by increased activity of SHP2-regulated pathways. Navire’s compounds are designed to act as “molecular glue” by …

Navire Pharma, a subsidiary of BridgeBio Pharma, and in collaboration with the Institute for Applied Cancer Science at MD Anderson, is developing inhibitors of SHP2 as targeted …

Uma Sinha, Ph.D., is the chief scientific officer of Navire Pharma. She has extensive experience in discovery and preclinical development of drug candidates across multiple therapeutic areas. …

Since joining the MD Anderson Cancer Center, he has brought together a team of drug discovery scientists who successfully assembled and advanced a portfolio of projects, including SHP2 …

Michael Henderson, M.D. is the Chief Executive Officer of Navire and the Chief Business Officer of BridgeBio. Learn more about our team today!

Shafique Virani, M.D., is chief executive officer for Navire Therapeutics and CEO-in-Residence at BridgeBio Pharma. Dr. Virani brings 13 years of experience in big pharma, and helped build an …

• MD Anderson and Navire pharma have developed IACS-13909, a potent and selective allosteric inhibitor of SHP2 • IACS-13909 potently suppresses the proliferation of cell lines driven by a …

Rick Panicucci, Ph.D. is the Senior Vice President of CMC at Navire Pharma, an affiliate company of BridgeBio. Prior to joining BridgeBio, Rick served as VP of Pharmaceutical Development …

Elizabeth Woodling is the Senior Vice President of Quality Assurance at Navire and serves in this role at other BridgeBio affiliates, including QED Therapeutics and BridgeBio Gene Therapy.

Dr. Anjali Pandey serves as Executive Vice President of Small Molecule Drug Discovery Research & Development for Navire Pharma and for BridgeBio.